Literature DB >> 22231115

Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk.

Stian Knappskog1, Per E Lønning.   

Abstract

The proto-oncogene MDM2 inhibits p53 and plays a key role in cell growth control and apoptosis. Identification of two antagonizing MDM2 polymorphisms, SNP285 and SNP309, affecting cancer risk through modulation of Sp1 transcription factor binding, shed new light on the biological activity and phylogeny of this gene.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22231115      PMCID： PMC3265776          DOI： 10.4161/trns.2.5.16813

Source DB:  PubMed          Journal:  Transcription        ISSN： 2154-1272


  25 in total

1.  A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.

Authors:  Sean M Post; Alfonso Quintás-Cardama; Vinod Pant; Tomoo Iwakuma; Amir Hamir; James G Jackson; Daniela R Maccio; Gareth L Bond; David G Johnson; Arnold J Levine; Guillermina Lozano
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

2.  BCR/ABL activates mdm2 mRNA translation via the La antigen.

Authors:  Rossana Trotta; Tatiana Vignudelli; Olivia Candini; Robert V Intine; Luisa Pecorari; Clara Guerzoni; Giorgia Santilli; Mike W Byrom; Silvia Goldoni; Lance P Ford; Michael A Caligiuri; Richard J Maraia; Danilo Perrotti; Bruno Calabretta
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

3.  The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.

Authors:  Stian Knappskog; Merete Bjørnslett; Line M Myklebust; Petra E A Huijts; Maaike P Vreeswijk; Hege Edvardsen; Yongli Guo; Xuemei Zhang; Ming Yang; Sanna K Ylisaukko-Oja; Pia Alhopuro; Johanna Arola; Rob A E M Tollenaar; Christi J van Asperen; Caroline Seynaeve; Vidar Staalesen; Ranjan Chrisanthar; Erik Løkkevik; Helga B Salvesen; D Gareth Evans; William G Newman; Dongxin Lin; Lauri A Aaltonen; Anne-Lise Børresen-Dale; Grethe S Tell; Camilla Stoltenberg; Pål Romundstad; Kristian Hveem; Johan R Lillehaug; Lars Vatten; Peter Devilee; Anne Dørum; Per E Lønning
Journal:  Cancer Cell       Date:  2011-02-15       Impact factor: 31.743

4.  Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase.

Authors:  Hiroyuki Inuzuka; Alan Tseng; Daming Gao; Bo Zhai; Qing Zhang; Shavali Shaik; Lixin Wan; Xiaolu L Ang; Caroline Mock; Haoqiang Yin; Jayne M Stommel; Steven Gygi; Galit Lahav; John Asara; Zhi-Xiong Jim Xiao; William G Kaelin; J Wade Harper; Wenyi Wei
Journal:  Cancer Cell       Date:  2010-08-09       Impact factor: 31.743

5.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

Review 6.  MDM2--master regulator of the p53 tumor suppressor protein.

Authors:  J Momand; H H Wu; G Dasgupta
Journal:  Gene       Date:  2000-01-25       Impact factor: 3.688

7.  ATM gene mutations result in both recessive and dominant expression phenotypes of genes and microRNAs.

Authors:  Denis A Smirnov; Vivian G Cheung
Journal:  Am J Hum Genet       Date:  2008-08       Impact factor: 11.025

8.  MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies.

Authors:  Zhibin Hu; Guangfu Jin; Lu Wang; Feng Chen; Xinru Wang; Hongbing Shen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-12       Impact factor: 4.254

Review 9.  Novel insights into the molecular mechanisms governing Mdm2 ubiquitination and destruction.

Authors:  Hiroyuki Inuzuka; Hidefumi Fukushima; Shavali Shaik; Wenyi Wei
Journal:  Oncotarget       Date:  2010-11

10.  MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk.

Authors:  Stian Knappskog; Per E Lønning
Journal:  Oncotarget       Date:  2011-03
View more
  22 in total

1.  Association between MDM2-SNP309 and p53R72P polymorphisms and the risk of bladder cancer in the Mongolian population.

Authors:  Shiirevnyamba Avirmed; Bo-Shen Wang; Baasansuren Selenge; Amarsaikhan Sanjaajamts; Batmunkh Ganbat; Ulziisaikhan Erdenebileg; Myagmarsuren Purevsuren; Sarantsetseg Jigjidsuren; Munkhbat Batmunkh; Yi-Jang Lee
Journal:  Mol Clin Oncol       Date:  2017-07-13

Review 2.  Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.

Authors:  Amanda R Wasylishen; Guillermina Lozano
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

3.  Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures.

Authors:  Charlotte Sagne; Virginie Marcel; Maria Bota; Ghyslaine Martel-Planche; Amanda Nobrega; Edenir Inêz Palmero; Laury Perriaud; Mathieu Boniol; Stephan Vagner; David G Cox; Chang S Chan; Jean-Louis Mergny; Magali Olivier; Patricia Ashton-Prolla; Janet Hall; Pierre Hainaut; Maria Isabel Achatz
Journal:  Carcinogenesis       Date:  2013-12-11       Impact factor: 4.944

4.  Association between murine double minute 2 T309G polymorphism and risk of liver cancer.

Authors:  Tao Tang; Xin Song; Zhiying Yang; Linping Huang; Wenyue Wang; Haidong Tan
Journal:  Tumour Biol       Date:  2014-08-14

5.  Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.

Authors:  Francesca Ponti; Serena Corsini; Maria Gnoli; Elena Pedrini; Marina Mordenti; Luca Sangiorgi
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

6.  Polymorphisms in the MDM2 gene and risk of malignant bone tumors: a meta-analysis.

Authors:  Jianfei Tang; Longxiang Shen; Sa Song; Zhiquan An; Changqing Zhang
Journal:  Tumour Biol       Date:  2013-08-27

7.  Functional role of post-translational modifications of Sp1 in tumorigenesis.

Authors:  Wen-Chang Chang; Jan-Jong Hung
Journal:  J Biomed Sci       Date:  2012-11-14       Impact factor: 8.410

8.  Esculetin, a Coumarin Derivative, Exhibits Anti-proliferative and Pro-apoptotic Activity in G361 Human Malignant Melanoma.

Authors:  Young-Joo Jeon; Jeong-Yun Jang; Jung-Hyun Shim; Pyung Keun Myung; Jung-Il Chae
Journal:  J Cancer Prev       Date:  2015-06

9.  MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.

Authors:  Hans Olsson; Per Hultman; Johan Rosell; Peter Söderkvist; Staffan Jahnson
Journal:  BMC Urol       Date:  2013-01-28       Impact factor: 2.264

10.  Murine Double-Minute 2 Homolog Single Nucleotide Polymorphisms 285 and 309 in Cervical Carcinogenesis.

Authors:  Andrzej Roszak; Matthew Misztal; Anna Sowińska; Pawel P Jagodziński
Journal:  Mol Diagn Ther       Date:  2015-08       Impact factor: 4.074
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.